EQUILLIUM, INC. Deferred Revenue
EQUILLIUM, INC. (EQ) had Deferred Revenue of $2.07 million as of 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2025-03-27
- 2024-09-30: Deferred Revenue, Current $2.07M.
- 2024-06-30: Deferred Revenue, Current $8.43M.
- 2024-03-31: Deferred Revenue, Current $13.36M.
- 2023-12-31: Deferred Revenue, Current $15.73M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2024-09-30 | $2.07M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $8.43M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $13.36M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $15.73M 10-K · filed 2025-03-27 |
| 2023-09-30 | $15.83M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $14.24M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $14.77M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $14.70M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |